Cinclus Pharma (CINPHA) investor relations material

Executive summary

• Linaprazan glurate, a next-generation PCAB, targets severe erosive GERD with sustained 24-hour acid control and clinical differentiation from PPIs and first-generation PCABs, offering a strong competitive advantage.

• Phase III HEEALING 1 study is nearing full enrollment, with topline results expected in Q4 2026, representing a major value catalyst.

• Commercial launch in China achieved via Sinorda's partnership with Huadong, with national reimbursement secured; Zentiva license for Europe valued at up to €220 million.

• Positive regulatory feedback from EMA and FDA, with FDA allowing a single pivotal study for US approval, streamlining the regulatory pathway.

• EUR 28 million financing agreement secured with Claret Capital Partners, with EUR 8 million drawn in Q1 to support late-stage clinical development.

Financial highlights

• Q1 2026 net sales reached SEK 10 million (TSEK 10,036), up from zero last year, driven by license income and China revenue.

• R&D expenses rose to SEK 91 million (TSEK -91,273), up 137% year-over-year, reflecting phase III trial activity.

• Operating loss widened to SEK 91 million (TSEK -90,854) from SEK 47 million (TSEK -47,519) in Q1 2025, mainly due to higher R&D costs.

• Net loss for Q1 2026 was SEK 88.8 million (TSEK -88,768), with EPS at SEK -1.91 (-0.72) before and after dilution.

• Cash and cash equivalents at period end were SEK 475.8 million (TSEK 475,849), down SEK 48.1 million year-over-year.

Outlook and guidance

• Sufficient funding secured to support operations through Q3 2027, covering the completion of the first Phase III program.

• Cost base will remain high in coming quarters due to ongoing phase III activities, with reduction expected after trial completion.

• Preparations for HEEALING 2 phase III trial are underway, aiming for a 2027 start, contingent on HEEALING 1 results.

• Financing agreement enables accelerated development and earlier start of final Phase III stages.